Shares of Pacific Biosciences of California (NASDAQ:PACB) surged 6.1% after ARK Invest bought 423,426 shares for $724,058. This move was part of portfolio adjustments, signaling a tilt toward the biotech sector. The shares closed at $1.88, up 8.4% from previous close. The market sees this news as significant but not game-changing. PacBio has seen 83 moves >5% in the past year, with a recent 4.5% gain due to advances in RNA sequencing for lung cancer research. Analysts remain positive, rating the stock a “Buy.” Despite a 4.4% increase YTD, it is still 28.5% below its 52-week high.

Investors eyeing PacBio as shares rise 6.1% after Cathie Wood’s ARK Invest buys 423,426 shares for $724,058, part of a strategic shift towards biotech. Market deems news significant but not transformative, with PacBio experiencing 83 moves >5% over the last year. Recent 4.5% gain linked to advances in RNA sequencing for lung cancer research. Stock up 4.4% YTD but still 28.5% below 52-week high. Analysts maintain “Buy” rating.

Read more at Barchart: Why Is PacBio (PACB) Stock Soaring Today